title: Survey of hospital policies regarding low-molecular-weight heparins.
abstract: Hospital policies regarding the use of low-molecular-weight heparins (LMWHs) were studied. A questionnaire addressing the formulary status of LMWH products, the use of prescribing guidelines, programs for therapeutic interchange, and policies to promote alternatives to LMWHs when appropriate was prepared. The questionnaire was mailed in January 2001 to pharmacy directors at 70 hospitals located in 19 states. All the hospitals were members of a national group purchasing organization. Forty-nine usable responses were received, for a response rate of 70%. Enoxaparin and dalteparin were the LMWH products most likely to be on the respondents' formularies (98% and 29% of hospitals, respectively). About 29% of the hospitals reported having guidelines on the use of LMWHs. Among hospitals that did not, most indicated that they were considering or would like to implement such guidelines. The most commonly cited barrier to the development and implementation of guidelines was lack of pharmacy personnel. Ten percent of the respondents reported having therapeutic-interchange programs for LMWHs. Cited barriers to therapeutic interchange programs included lack of therapeutic equivalence among products and lack of comparable labeled indications. Policies to promote alternatives to LMWHs were reported by 18% of the respondents. A multihospital survey showed that many hospitals wanted but relatively few had prescribing guidelines for LMWHs.
authors.affiliation: Department of Pharmacy Practice, University of Illinois at Chicago, 833 S. Wood Street (M/C 886), Chicago, IL 60612, USA. schumock@uic.edu
authors.forename: Glen T
authors.initials: GT
authors.lastname: Schumock
authors.forename: Edith A
authors.initials: EA
authors.lastname: Nutescu
authors.forename: Surrey M
authors.initials: SM
authors.lastname: Walton
authors.forename: Bhakti V
authors.initials: BV
authors.lastname: Arondekar
authors.forename: Richard K
authors.initials: RK
authors.lastname: Lewis
mesh_terms: D017985:Dalteparin / Q000627:therapeutic use; D017723:Drug Utilization Review; D016568:Drugs, Generic / Q000627:therapeutic use*; D017984:Enoxaparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005572:Formularies, Hospital as Topic; D017754:Group Purchasing; D019538:Health Care Surveys; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D016134:Organizational Policy; D010607:Pharmacy Service, Hospital / Q000458:organization & administration* / Q000592:standards / Q000706:statistics & numerical data*; D017410:Practice Guidelines as Topic; D011795:Surveys and Questionnaires; D013810:Therapeutic Equivalency; D014481:United States
chemical_list: D016568:Drugs, Generic; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017985:Dalteparin